Merck & Co. Inc. [MRK] Revenue clocked in at $47.70 billion, up 0.30% YTD: What’s Next?

Related

Share

Merck & Co. Inc. [NYSE: MRK] traded at a high on 01/03/22, posting a 0.30 gain after which it closed the day’ session at $76.87. The company report on December 28, 2021 that Merck and Ridgeback’s Molnupiravir Receives U.S. FDA Emergency Use Authorization for the Treatment of High-Risk Adults With Mild to Moderate COVID-19.

The Companies Are Committed To Providing Timely Access to Molnupiravir Through Comprehensive Supply and Access Approach.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


The results of the trading session contributed to over 9243461 shares changing hands. Over the past one week, the price volatility of Merck & Co. Inc. stands at 1.26% while the volatility over the past one month is 1.70%.

The market cap for MRK stock reached $195.27 billion, with 2.53 billion shares outstanding and 2.52 billion shares in the current float. Compared to the average trading volume of 16.06M shares, MRK reached a trading volume of 9243461 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Merck & Co. Inc. [MRK]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MRK shares is $92.31 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MRK stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Goldman have made an estimate for Merck & Co. Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 17, 2021. While these analysts kept the previous recommendation, Daiwa Securities raised their target price to Neutral. The new note on the price target was released on December 16, 2021, representing the official price target for Merck & Co. Inc. stock. Previously, the target price had yet another drop from $98 to $76, while UBS kept a Neutral rating on MRK stock.

The Average True Range (ATR) for Merck & Co. Inc. is set at 1.49, with the Price to Sales ratio for MRK stock in the period of the last 12 months amounting to 4.09. The Price to Book ratio for the last quarter was 5.43. Price to Free Cash Flow for MRK in the course of the last twelve months was 107.23 with Quick ratio for the last quarter at 1.10.

How has MRK stock performed recently?

Merck & Co. Inc. [MRK] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.39. With this latest performance, MRK shares gained by 4.03% in over the last four-week period, additionally sinking by -1.59% over the last 6 months – not to mention a drop of -0.42% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MRK stock in for the last two-week period is set at 51.04, with the RSI for the last a single of trading hit 56.60, and the three-weeks RSI is set at 48.86 for Merck & Co. Inc. [MRK]. The present Moving Average for the last 50 days of trading for this stock 79.42, while it was recorded at 76.88 for the last single week of trading, and 77.48 for the last 200 days.

Merck & Co. Inc. [MRK]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Merck & Co. Inc. [MRK] shares currently have an operating margin of +26.16 and a Gross Margin at +73.77. Merck & Co. Inc.’s Net Margin is presently recorded at +14.72.

Return on Total Capital for MRK is now 22.39, given the latest momentum, and Return on Invested Capital for the company is 13.93. Return on Equity for this stock inclined to 27.59, with Return on Assets sitting at 8.03. When it comes to the capital structure of this company, Merck & Co. Inc. [MRK] has a Total Debt to Total Equity ratio set at 132.14. Additionally, MRK Total Debt to Total Capital is recorded at 56.92, with Total Debt to Total Assets ending up at 36.53. Long-Term Debt to Equity for the company is recorded at 105.55, with the Long-Term Debt to Total Capital now at 45.47.

Reflecting on the efficiency of the workforce at the company, Merck & Co. Inc. [MRK] managed to generate an average of $95,500 per employee. Receivables Turnover for the company is 6.56 with a Total Asset Turnover recorded at a value of 0.55.Merck & Co. Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.10 and a Current Ratio set at 1.30.

Earnings analysis for Merck & Co. Inc. [MRK]

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MRK. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Merck & Co. Inc. go to 15.33%.

>> 7 Top Picks for the Post-Pandemic Economy <<

Insider trade positions for Merck & Co. Inc. [MRK]

There are presently around $139,874 million, or 74.80% of MRK stock, in the hands of institutional investors. The top three institutional holders of MRK stocks are: VANGUARD GROUP INC with ownership of 210,468,088, which is approximately -6.688% of the company’s market cap and around 0.07% of the total institutional ownership; BLACKROCK INC., holding 187,897,289 shares of the stock with an approximate value of $14.4 billion in MRK stocks shares; and STATE STREET CORP, currently with $8.85 billion in MRK stock with ownership of nearly 1.282% of the company’s market capitalization.

Positions in Merck & Co. Inc. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 1,339 institutional holders increased their position in Merck & Co. Inc. [NYSE:MRK] by around 72,461,804 shares. Additionally, 1,084 investors decreased positions by around 81,542,625 shares, while 315 investors held positions by with 1,671,077,247 shares. The mentioned changes placed institutional holdings at 1,825,081,676 shares, according to the latest SEC report filing. MRK stock had 105 new institutional investments in for a total of 8,589,962 shares, while 102 institutional investors sold positions of 13,942,173 shares during the same period.